The outcomes of multiple myeloma (MM) have been improved significantly with the therapies incorporating proteasome inhibitors (PI), immunomodulatory drugs, monoclonal antibodies (MoAb) and stem cell transplantation. However, relapsed and refractory MM (RRMM) remains a major challenge. Novel agents and regimens are under active clinical development. These include new PIs such as ixazomib, marizomib, and oprozomib; new MoAbs such as isatuximab and MOR202; novel epigenetic agent ricolinostat and novel cytokines such as siltuximab. Recently, the first XPO-1 inhibitor, selinexor, was approved for RRMM. BCMA-targeted BiTE, antibody–drug conjugates and CAR-T cells have the potential to revolutionize the therapy for RRMM. In this review, we summarized the latest clinical development of these novel agents and regimens.
CITATION STYLE
Yang, Y., Li, Y., Gu, H., Dong, M., & Cai, Z. (2020, December 1). Emerging agents and regimens for multiple myeloma. Journal of Hematology and Oncology. BioMed Central Ltd. https://doi.org/10.1186/s13045-020-00980-5
Mendeley helps you to discover research relevant for your work.